The BE (2)-M17 cell line has a better dopaminergic phenotype than the traditionally used for Parkinson's research SH-SY5Y, which is mostly serotonergic

被引：8

作者：

Carvajal-Oliveros, Angel ^{[1
]}

Uriostegui-Arcos, Maritere ^{[1
,2
]}

Zurita, Mario ^{[1
]}

Melchy-Perez, Erika I. ^{[1
]}

Narvaez-Padilla, Veronica ^{[3
]}

Reynaud, Enrique ^{[1
]}

机构：

[1] Univ Nacl Autonoma Mexico, Inst Biotecnol, Cuernavaca 62210, Morelos, Mexico

[2] Boston Univ, Dept Biol, Boston, MA USA

[3] Univ Autonoma Estado Morelos, Ctr Invest Dinam Celular, Cuernavaca, Mexico

来源：

IBRO NEUROSCIENCE REPORTS | 2022年 / 13卷

关键词：

SH-SY5Y cell line; Parkinson's disease; Dopaminergic neurons; Serotonergic neurons; Staurosporine; Retinoic acid; IN-VITRO MODEL; ALPHA-SYNUCLEIN; DISEASE;

D O I：

10.1016/j.ibneur.2022.11.007

中图分类号：

Q189 [神经科学];

学科分类号：

071006 ;

摘要：

SH-SY5Y is a cell line derived from human neuroblastoma. It is one of the most widely used in vitro models to study Parkinson's disease. Surprisingly, it has been found that it does not develop a dopaminergic phenotype after differentiation, questioning its usefulness as a Parkinson's model. There are other in vitro models with better dopaminergic characteristics. BE (2)-M17 is a human neuroblastoma cell line that differentiates when treated with retinoic acid. We compared the dopaminergic and serotonergic properties of both cell lines. BE (2)-M17 has higher basal levels of dopaminergic markers and acquires a serotonergic phenotype during differentiation while maintaining the dopaminergic phenotype. SH-SY5Y has higher basal levels of serotonergic markers but does not acquire a dopaminergic phenotype upon differentiation.

引用

页码：543 / 551

页数：9

共 33 条

[11] Cellular models for Parkinson's disease [J].

Falkenburger, Bjoern H. ;

Saridaki, Theodora ;

Dinter, Elisabeth .

JOURNAL OF NEUROCHEMISTRY, 2016, 139 :121-130

[12] Analysis of the Catecholaminergic Phenotype in Human SH-SY5Y and BE(2)-M17 Neuroblastoma Cell Lines upon Differentiation [J].

Filograna, Roberta ;

Civiero, Laura ;

Ferrari, Vanni ;

Codolo, Gaia ;

Greggio, Elisa ;

Bubacco, Luigi ;

Beltramini, Mariano ;

Bisaglia, Marco .

PLOS ONE, 2015, 10 (08)

[13]

Gazewood JD, 2013, AM FAM PHYSICIAN, V87, P267

[14] Data Descriptor: Transcriptomic profiling of 39 commonly-used neuroblastoma cell lines [J].

Harenza, Jo Lynne ;

Diamond, Maura A. ;

Adams, Rebecca N. ;

Song, Michael M. ;

Davidson, Heather L. ;

Hart, Lori S. ;

Dent, Maiah H. ;

Fortina, Paolo ;

Reynolds, C. Patrick ;

Maris, John M. .

SCIENTIFIC DATA, 2017, 4

[15] VMAT2 inhibitors for the treatment of hyperkinetic movement disorders [J].

Koch, Jessa ;

Shi, Wei-Xing ;

Dashtipour, Khashayar .

PHARMACOLOGY & THERAPEUTICS, 2020, 212

[16] Phenotypic Characterization of Retinoic Acid Differentiated SH-SY5Y Cells by Transcriptional Profiling [J].

Korecka, Joanna A. ;

van Kesteren, Ronald E. ;

Blaas, Eva ;

Spitzer, Sonia O. ;

Kamstra, Jorke H. ;

Smit, August B. ;

Swaab, Dick F. ;

Verhaagen, Joost ;

Bossers, Koen .

PLOS ONE, 2013, 8 (05)

[17]

Kovalevich J, 2013, METHODS MOL BIOL, V1078, P9, DOI 10.1007/978-1-62703-640-5_2

[18] Early environmental origins of neurodegenerative disease in later life [J].

Landrigan, PJ ;

Sonawane, B ;

Butler, RN ;

Trasande, L ;

Callan, R ;

Droller, D .

ENVIRONMENTAL HEALTH PERSPECTIVES, 2005, 113 (09) :1230-1233

[19] Monoamine Transporters: Vulnerable and Vital Doorkeepers [J].

Lin, Zhicheng ;

Canales, Juan J. ;

Bjoergvinsson, Throestur ;

Thomsen, Morgane ;

Qu, Hong ;

Liu, Qing-Rong ;

Torres, Gonzalo E. ;

Caine, S. Barak .

BRAIN AS A DRUG TARGET, 2011, 98 :1-46

[20] Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCT method [J].

Livak, KJ ;

Schmittgen, TD .

METHODS, 2001, 25 (04) :402-408

← 1 2 3 4 →